Azitra, INC S-1 registration statements

Azitra, Inc. has filed an S-1 registration statement for the resale of up to 255,699,381 shares of its common stock by selling stockholders, following a private placement.

Azitra, Inc. files an S-1 registration statement for the resale of over 51 million shares by selling stockholders, including those from recent capital raises, while facing NYSE American minimum equity non-compliance.

Azitra, an early-stage biopharmaceutical company, announced a best-efforts public offering of common stock and pre-funded warrants to raise up to $10 million for its precision dermatology programs, following a recent 1-for-6.66 reverse stock split and a 'going concern' warning.

Biopharmaceutical company Azitra, Inc. filed an S-1 registration statement to allow selling stockholders to resell up to 2.2 million shares underlying warrants, while acknowledging substantial doubt about its ability to continue as a going concern and a significant drop in its stock price since its 2023 IPO.

Azitra Inc. has filed a registration statement for the potential resale of up to 66,889,632 shares of common stock and 6,688,963 shares underlying warrants by Alumni Capital LP, aiming to raise up to $22.6 million for working capital and general corporate purposes.

Azitra, Inc., a clinical-stage biopharmaceutical company, has filed an amendment to its S-1 registration statement for a public offering of up to 3,115,265 units, each consisting of one share of common stock or one pre-funded warrant and two Class A warrants, aiming to raise up to $10 million.

Azitra Inc. is launching a public offering of units, including common stock and warrants, to advance its clinical biopharmaceutical programs in precision dermatology.

Azitra, Inc. is planning to raise capital through an offering of common stock and pre-funded warrants, according to a recent S-1 filing.